CLSN Key Stats
- Celsion Prepares For Phase III Trial Redux Seeking Alpha Nov 27
- Investors Should Avoid Celsion At All Costs Wall St. Cheat Sheet Nov 26
- CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio Nov 26
- Celsion Corporation Announces Strategic Loan Facility noodls Nov 26
- Could 2014 Bring A New Air To Celsion? Seeking Alpha Nov 18
- Celsion's CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 12
- Celsion Corporation Discusses Q3 2013 Results (Webcast) Seeking Alpha Nov 12
- CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements an Nov 12
- Celsion Corp. (CLSN) Narrows Q3 Loss to 30c/Share Street Insider Nov 12
- Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update noodls Nov 12
CLSN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Celsion is down 88.68% over the last year vs S&P 500 Total Return up 30.68%, ARCA biopharma down 8.05%, and OxiGene down 43.11%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for CLSN
Pro Strategies Featuring CLSN
Did Celsion make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Celsion Corporation is an innovative oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer.